Temporomandibular Disorders (TMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Temporomandibular disorder (TMD) encompasses conditions affecting the orofacial region, specifically the masticatory muscles and temporomandibular joint (TMJ). TMD is characterized by pain in the TMJ, restricted mandibular movement, and TMJ sounds. The etiology of TMD is not fully understood, but it is believed to involve multiple factors. Myofascial and intraarticular TMDs differ in their underlying causes. Myofascial TMD is characterized by tension, fatigue, and pain in the masticatory muscles. Various factors contribute to muscular dysfunction, including stress, parafunctional habits like bruxism, abnormal posture, and psychological conditions. Chronic pain conditions such as fibromyalgia are also commonly associated with TMD. Intraarticular TMD refers to inflammatory or mechanical factors affecting the TMJ, with articular disc displacement being the most prevalent. Common signs and symptoms of TMD include jaw discomfort or soreness, headaches, pain in the face, neck, shoulder, or back, earaches or tinnitus unrelated to inner ear infections, and teeth clenching. The National Institute of Dental and Craniofacial Research classifies TMD into myofascial pain, internal derangement of the joint, and degenerative joint disease. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line pharmacological treatment for both acute and chronic forms of TMD. Benzodiazepines may be prescribed for recurrent masticatory muscle spasms and bruxism when relaxation techniques have failed. Tricyclic antidepressants can be considered for symptom improvement based on their effectiveness in other pain disorders. TMD is the second most prevalent musculoskeletal pain condition, with low back pain being the most common.

  • Worldwide, the prevalence of TMD pain in children ranges from 0.2% to 28%, while the occurrence of TMJ pain varies from 0.7% to 4%, depending on age. Among adults, the estimated prevalence ranges from 2% to 8% for males and 4% to 15% for females.

Thelansis’s “Temporomandibular Disorders (TMD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Temporomandibular Disorders (TMD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Temporomandibular Disorders (TMD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Temporomandibular Disorders (TMD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Temporomandibular Disorders (TMD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more